Exelixis Inc. (NASDAQ: EXEL) is 6.48% higher on its value in year-to-date trading and has touched a low of $13.67 and a high of $27.80 in the current 52-week trading range. The EXEL stock was last observed hovering at around $20.53 in the last trading session, with the day’s gains setting it 0.84% off its average median price target of $30.00 for the next 12 months. It is also 46.58% off the consensus price target high of $40.00 offered by 12 analysts, but current levels are 14.52% higher than the price target low of $25.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $21.37, the stock is 7.01% and 6.06% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.14 million and changing 4.09% at the moment leaves the stock -3.87% off its SMA200. EXEL registered 21.73% gain for a year compared to 6-month loss of -8.56%. The firm has a 50-day simple moving average (SMA 50) of $19.60 and a 200-day simple moving average (SMA200) of $22.21.
The stock witnessed a 13.43% gain in the last 1 month and extending the period to 3 months gives it a -10.88%, and is 4.70% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.84% over the week and 3.20% over the month.
Exelixis Inc. (EXEL) has around 617 employees, a market worth around $6.65B and $957.80M in sales. Current P/E ratio is 44.61 and Fwd P/E is 52.90. Profit margin for the company is 15.90%. Distance from 52-week low is 56.33% and -23.13% from its 52-week high. The company has generated returns on investments over the last 12 months (17.30%).
Exelixis Inc. (EXEL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Exelixis Inc. (EXEL) is a “Overweight”. 12 analysts offering their recommendations for the stock have an average rating of 2.00, where 3 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Exelixis Inc. is expected to release its quarterly report on 05/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.07 with sales reaching $213.78M over the same period.The EPS is expected to shrink by -53.80% this year, but quarterly earnings will post -3.80% year-over-year. Quarterly sales are estimated to shrink -11.00% in year-over-year returns.
Exelixis Inc. (EXEL) Top Institutional Holders
518 institutions hold shares in Exelixis Inc. (EXEL), with 5.76M shares held by insiders accounting for 1.86% while institutional investors hold 86.20% of the company’s shares. The shares outstanding are 309.12M, and float is at 302.86M with Short Float at 4.75%. Institutions hold 84.60% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 30.63 million shares valued at $748.82 million. The investor’s holdings represent 9.87% of the EXEL Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 27.79 million shares valued at $679.49 million to account for 8.96% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 22.67 million shares representing 7.31% and valued at over $554.17 million, while Price (T.Rowe) Associates Inc holds 4.40% of the shares totaling 13.64 million with a market value of $333.53 million.
Exelixis Inc. (EXEL) Insider Activity
The most recent transaction is an insider sale by Lamb Peter, the company’s EVP, Scientific Strategy & CSO. SEC filings show that Lamb Peter sold 65,000 shares of the company’s common stock on Dec 18 at a price of $20.01 per share for a total of $1.3 million. Following the sale, the insider now owns 0.28 million shares.
Exelixis Inc. disclosed in a document filed with the SEC on Nov 24 that MARCHESI VINCENT T (Director) sold a total of 40,004 shares of the company’s common stock. The trade occurred on Nov 24 and was made at $18.50 per share for $0.74 million. Following the transaction, the insider now directly holds 90212.0 shares of the EXEL stock.
Still, SEC filings show that on Nov 10, WYSZOMIERSKI JACK L (Director) disposed off 34,000 shares at an average price of $20.61 for $0.7 million. The insider now directly holds 197,809 shares of Exelixis Inc. (EXEL).
Exelixis Inc. (EXEL): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 9.88% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is -2.27% down on the 1-year trading charts. Short interest in the company’s stock has risen 5.29% from the last report on Nov 12, 2020 to stand at a total of 13.62 million short shares sold with a short interest ratio of 6.31.